Oscar Health (OSCR) Q2 2026 earnings review
The Repricing Strategy Pays Off: Record Profitability and a Massive Guidance Hike
Oscar Health's aggressive 28% rate hikes for 2026 have successfully completely altered the company's trajectory. Revenue surged 70% YoY to $4.88B, but more importantly, profitability is reversing course from deep losses to a record $361.8M Net Income in Q2. The core mechanism is medical cost control: the Medical Loss Ratio (MLR) collapsed by nearly 12 percentage points YoY to 79.2%. While $164M of favorable prior-period development flatters these results, the underlying operational leverage is undeniable. Management confidently raised FY26 Earnings from Operations guidance by $250M at the midpoint, signaling that the 2025 'market reset' is firmly in the rearview mirror.
🐂 Bull Case
Oscar's 28% weighted average rate increase for 2026 stuck without destroying the risk pool. The MLR improvement from 91.1% to 79.2% validates their underwriting and pricing models.
SG&A ratio hit 14.2%, an accelerating improvement of 450 bps YoY. The company is successfully leveraging AI and its tech stack to service 46% more members with a tighter fixed cost base.
🐻 Bear Case
The Q2 profitability beat was heavily subsidized by $164M of favorable prior period reserve development. Without this one-time tailwind, the MLR and net income would look far more normalized.
Membership is decelerating sequentially, dropping from 3.17M in Q1 2026 to 2.96M in Q2. While expected due to non-payments and the end of open enrollment, the absolute loss of over 200,000 covered lives pressures future top-line growth.
⚖️ Verdict: 🟢🟢
Bullish. Management executed a textbook turnaround. They correctly diagnosed the 2025 morbidity shift, aggressively repriced, retained volume, and are now reaping the rewards of immense operating leverage.
Key Themes
Medical Loss Ratio (MLR) Cratering
The single most important metric for Oscar is reversing sharply in a positive direction. The Q2 MLR of 79.2% is a massive 1190 bps improvement YoY. This proves the ~28% premium increases implemented for the 2026 plan year successfully outpaced medical cost trends and the lingering effects of 2025's Medicaid redeterminations.
AI-Driven SG&A Leverage
Oscar's narrative as a 'tech-first' insurer is supported by the data. The SG&A ratio dropped to 14.2%, a 450 bps YoY improvement. Management attributes this to strict expense management, greater fixed cost leverage against a $4.8B revenue base, and the continued deployment of AI tools (like their 'Oswell' agent and Agentic AI bots) to handle member queries with less headcount.
Macro Tailwinds: The Gig Work Shift
CEO Mark Bertolini explicitly tied Oscar's individual market opportunity to a macro workforce shift. More Americans are moving to part-time jobs, gig work, or early retirement—a trend management believes AI will accelerate. This structural shift detaches health insurance from traditional corporate employers, creating a permanently expanded total addressable market for Oscar's core ACA and ICHRA products.
Earnings Inflated by Prior Period Adjustments
A specific data point contradicts the purely positive operational narrative: Q2 results included $164 million of favorable prior period reserve development. If we back out this non-recurring benefit, the MLR would be approximately 3.4 percentage points higher (closer to 82.6%), and operating earnings would be cut nearly in half. Investors must monitor whether core Q3/Q4 claims can sustain these margins without back-year true-ups.
Membership Sequential Deceleration
While YoY membership growth remains a robust 46%, the sequential trend is decelerating. Total members fell from 3.17 million in Q1 2026 to 2.96 million in Q2. Management previously guided for this exact churn (primarily tied to non-payments and grace period expirations), but a shrinking denominator puts more pressure on rate hikes to drive total revenue growth in H2 2026.
Risk Adjustment Accrual Normalization
Risk adjustment transfers remain a volatile line item. The net risk adjustment payable on the balance sheet ballooned to $4.84B in Q2 (up from $2.31B at the end of 2025). The seasonal normalization of medical claims through the back half of the year will mechanically shift the MLR higher, which is already reflected in the full-year MLR guidance of 81.5%-82.5%.
Other KPIs
Reversing dramatically from a loss of $199.4M in the same period last year. This brings H1 2026 Adjusted EBITDA to $1.14B, completely changing the cash generation profile of the business.
Accelerating significantly from $1.39B in H1 2025. This massive cash generation has fortified the balance sheet, bringing cash and short-term investments to over $8.5B, providing immense flexibility for debt management or reinvestment in the Lucie Health Marketplace.
Guidance
Accelerating. Raised significantly from the prior outlook of $250M - $450M. This implies strong confidence that the favorable claims environment and pricing actions will hold through the typically higher-utilization back half of the year.
Accelerating improvement. Lowered from the previous target of 82.4% - 83.4%. Given H1 2026 MLR averaged 75.0%, this implies a back-half MLR closer to the high-80s as deductibles are met, but still represents a massive YoY improvement.
Stable to improving. Trimmed from the prior 15.8% - 16.3% expectation. Shows that tech-driven efficiency gains are running slightly ahead of schedule.
Stable. The company maintained its top-line view despite the massive profitability beat. This suggests that the upside is entirely driven by margin expansion and cost control rather than unexpected volume growth.
Key Questions
Sustainability of Favorable Prior Period Development
With $164 million of the Q2 profitability beat coming from prior period reserve development, how much of this was related to 2025 risk adjustment true-ups versus pure claims run-out? Should we expect zero, or potentially negative, development in H2?
Sequential Membership Churn Dynamics
Membership dropped by roughly 211,000 lives sequentially in Q2. Is this churn curve matching your pre-ARPA historical models perfectly, or are higher 2026 out-of-pocket limits accelerating the drop-off?
Update on Wakely Data and Market Morbidity
Your prior guidance was built on conservative assumptions regarding market-wide morbidity. Does the $250 million raise to operating earnings guidance reflect new, concrete Wakely data showing market contraction is healthier than expected, or is it purely reflecting your own book's Q2 outperformance?